PortfoliosLab logoPortfoliosLab logo
NVCT vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVCT vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVCT achieves a 185.03% return, which is significantly higher than NVO's -4.23% return.


NVCT

1D
-5.45%
1M
9.96%
6M
165.35%
YTD
185.03%
1Y
216.47%
3Y*
16.05%
5Y*
10Y*
ALL TIME*
45.94%

NVO

1D
-8.78%
1M
-6.64%
6M
-18.01%
YTD
-4.23%
1Y
2.25%
3Y*
-14.32%
5Y*
2.48%
10Y*
7.55%
ALL TIME*
14.37%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$4.72M$5.59M$5.62M
$504.41M$480.49M$577.88M

NVCT vs. NVO - Yearly Performance Comparison


2026 (YTD)2025202420232022
NVCT
Nuvectis Pharma Inc
185.03%39.56%-35.13%11.20%89.87%
NVO
Novo Nordisk A/S
-4.23%-39.22%-15.93%54.84%31.30%

Correlation

The correlation between NVCT and NVO is 0.17, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.17

Correlation (3Y)
Balances recent behavior with more history.

0.10

Correlation (All Time)
Calculated using the full available price history since Feb 4, 2022

0.08

Fundamentals

Market Cap

NVCT:

$571.06M

NVO:

$209.19B

EPS

NVCT:

-$1.20

NVO:

DKK 27.42

PB Ratio

NVCT:

35.43

NVO:

6.70

Total Revenue (TTM)

NVCT:

$0.00

NVO:

DKK 327.80B

Gross Profit (TTM)

NVCT:

$0.00

NVO:

DKK 268.30B

EBITDA (TTM)

NVCT:

-$22.01M

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVCT vs. NVO — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

NVCT
NVCT Risk / Return Rank: 9494
Overall Rank
NVCT Sharpe Ratio Rank: 9595
Sharpe Ratio Rank
NVCT Sortino Ratio Rank: 9292
Sortino Ratio Rank
NVCT Omega Ratio Rank: 9494
Omega Ratio Rank
NVCT Calmar Ratio Rank: 9696
Calmar Ratio Rank
NVCT Martin Ratio Rank: 9595
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 4747
Overall Rank
NVO Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 4545
Sortino Ratio Rank
NVO Omega Ratio Rank: 4646
Omega Ratio Rank
NVO Calmar Ratio Rank: 4848
Calmar Ratio Rank
NVO Martin Ratio Rank: 4848
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

NVCT vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NVCTNVODifference
Sharpe ratioReturn per unit of total volatility

+2.42

Sortino ratioReturn per unit of downside risk

+2.47

Omega ratioGain probability vs. loss probability

1.44

1.06

+0.37

Calmar ratioReturn relative to maximum drawdown

5.72

0.11

+5.61

Martin ratioReturn relative to average drawdown

13.67

0.20

+13.47

NVCT vs. NVO - Sharpe Ratio Comparison

The current NVCT Sharpe Ratio is 2.52, which is higher than the NVO Sharpe Ratio of 0.10. The chart below compares the historical Sharpe Ratios of NVCT and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NVCT vs. NVO - Drawdown Comparison

The maximum NVCT drawdown since its inception was -77.89%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NVCT and NVO.


Loading charts...

Drawdown Indicators


NVCTNVODifference

Max Drawdown

Largest peak-to-trough decline

-77.89%

-74.70%

-3.19%

Max Drawdown (1Y)

Largest decline over 1 year

-36.80%

-43.67%

+6.87%

Max Drawdown (3Y)

Largest decline over 3 years

-70.48%

-74.70%

+4.22%

Max Drawdown (5Y)

Largest decline over 5 years

-74.70%

Max Drawdown (10Y)

Largest decline over 10 years

-74.70%

Current Drawdown

Current decline from peak

-24.57%

-65.79%

+41.22%

Average Drawdown

Average peak-to-trough decline

-52.49%

-17.93%

-34.56%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.38%

23.97%

-8.59%

Volatility

NVCT vs. NVO - Volatility Comparison

Nuvectis Pharma Inc (NVCT) has a higher volatility of 19.25% compared to Novo Nordisk A/S (NVO) at 12.28%. This indicates that NVCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVCTNVODifference

Volatility (1M)

Calculated over the trailing 1-month period

19.25%

12.28%

+6.97%

Volatility (6M)

Calculated over the trailing 6-month period

73.03%

36.87%

+36.16%

Volatility (1Y)

Calculated over the trailing 1-year period

84.10%

46.77%

+37.33%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

112.08%

38.76%

+73.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

112.08%

32.76%

+79.32%

Dividends

NVCT vs. NVO - Dividend Comparison

NVCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.83%.


PositionTTM20252024202320222021202020192018201720162015
NVCT
Nuvectis Pharma Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
3.83%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%

Financials

NVCT vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Nuvectis Pharma Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


NVCT and NVO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVCT has higher volatility (19.25%) compared to NVO (12.28%). In terms of maximum drawdown, NVCT dropped -77.89% vs NVO's -74.70%.

NVCT currently has the higher Sharpe Ratio (2.52 vs 0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVCT and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer